Search

Your search keyword '"Recte - Càncer - Prognosi"' showing total 4 results
Start Over Descriptor "Recte - Càncer - Prognosi"
4 results on '"Recte - Càncer - Prognosi"'

1. Prognostic significance of the microbiome–adipose tissue axis in rectal cancer: protocol of a prospective observational study

Author

Pere Planellas, Lídia Cornejo, Ramon Farrés, Anna Pigem, Ander Timoteo, Nuria Ortega, Gianluca Pellino, José-Ignacio Rodríguez-Hermosa, Eugeni López-Bonet, José Manuel Fernández-Real, Antoni Codina-Cazador, Institut Català de la Salut, [Planellas P, Farrés R] Colorectal Surgery Unit, Department of General and Digestive Surgery, University Hospital of Girona Dr. Josep Trueta, Girona, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain. Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain. [Cornejo L] Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Pigem A, Timoteo A, Ortega N] Colorectal Surgery Unit, Department of General and Digestive Surgery, University Hospital of Girona Dr. Josep Trueta, Girona, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Pellino G] Unitat de Cirurgia de Còlon i Recte, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Planellas, Pere, Cornejo, Lídia, Farrés, Ramon, Pigem, Anna, Timoteo, Ander, Ortega, Nuria, Pellino, Gianluca, Rodríguez-Hermosa, José-Ignacio, López-Bonet, Eugeni, Fernández-Real, José Manuel, and Codina-Cazador, Antoni

Subjects
Rectum -- Cancer, Prognosi, Rectal Neoplasms, Microbiota, Recte - Càncer - Prognosi, General Medicine, Prognosis, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto [ENFERMEDADES], Prospective Studie, Teixit adipós, Observational Studies as Topic, Adipose Tissue, Humans, Intestins - Microbiologia, Prospective Studies, Recte -- Càncer, Human
Abstract

Colorectal cancer is the second-leading oncological cause of death worldwide1. Despite advances in treatment, there is still a risk of local and distant recurrence, which impacts on long-term outcomes This study was awarded a grant by the ‘Asociación Española de Coloproctolgía’ and ‘Col·legi Oficial de Metges de Girona—Joan Bruguera Grant’ in 2021.

Published
2022

2. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer

Author

[Elez E, Sanz-García E, Noguerido A, Martini G, Macarulla T, Argilés G, Capdevila J, Garcia A, Tabernero J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Chianese C, Mancuso FM, Caratù G, Matito J, Vivancos A] Grup de Genòmica del Càncer, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Martinelli E] Medical Oncology, Department of Clinical and Experimental Medicine ‘F. Magrassi’, Università della Campania ‘L. Vanvitelli’, Napoli, Italy. [Grasselli J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain. [Mulet N] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain. and Hospital Universitari Vall d'Hebron

Subjects
Pathological Conditions, Signs and Symptoms::Pathologic Processes::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Citodiagnòstic, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], técnicas de investigación::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::técnicas de investigación::técnicas de laboratorio clínico::técnicas de investigación::biopsia líquida [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Metàstasi, Condiciones Patológicas, Signos y Síntomas::Procesos Patológicos::Procesos Neoplásicos::Metástasis de la Neoplasia [ENFERMEDADES], Recte - Càncer - Prognosi, Investigative Techniques::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Investigative Techniques::Clinical Laboratory Techniques::Investigative Techniques::Liquid Biopsy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], diagnóstico::pronóstico::estadificación de neoplasias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Neoplasm Staging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Neoplasias::Neoplasias por Localización::Neoplasias del Sistema Digestivo::Neoplasias Gastrointestinales::Neoplasias Intestinales::Neoplasias Colorrectales [ENFERMEDADES]
Published
2021

3. Lymph Node Tumor Burden Correlates With Tumor Budding and Poorly Differentiated Clusters: A New Prognostic Factor in Colorectal Carcinoma?

Author

Maria Teresa Rodrigo, Isidro Machado, Sandra Lopez-Prades, José Javier Aguirre, Iñigo Gorostiaga, Jordi Camps, Ivan Archilla, Jordi Tarragona, Miriam Cuatrecasas, Begoña Otero Alén, Stefania Landolfi, Sherley Diaz-Mercedes, Francesc Balaguer, Antoni Castells, Institut Català de la Salut, [Archilla I, Díaz-Mercedes S, Rodrigo MT] Pathology Department, Center of Biomedical Diagnosis (CDB), Hospital Clínic, University of Barcelona, IDIBAPS, Spain. [Aguirre JJ] Pathology Department, Arava University Hospital, Vitoria-Gasteiz, Spain. [Tarragona J] Pathology Department, Hospital Arnau de Vilanova, Lleida, Spain. [Machado I] Pathology Department, Instituto Valenciano de Oncologia and Hospital QuironSalud, Valencia, Spain. [Landolfi S] Department of Pathology, Hospital Universitario Torrecardenas, Almeria, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, Oncology, Colorectal cancer, H&E stain, Perineural invasion, 0302 clinical medicine, Other subheadings::/diagnosis [Other subheadings], Stage (cooking), Lymph node, Aged, 80 and over, Gastroenterology, Middle Aged, Prognosis, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], Tumor Burden, medicine.anatomical_structure, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Colorectal Neoplasms, Nodes limfàtics - Aspectes moleculars, medicine.medical_specialty, Colon, Otros calificadores::/diagnóstico [Otros calificadores], Risk Assessment, Article, Disease-Free Survival, Tissues::Lymphoid Tissue::Lymph Nodes [ANATOMY], 03 medical and health sciences, Cytokeratin, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Tumor budding, Internal medicine, medicine, Humans, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Carcinoma, Recte - Càncer - Prognosi, tejidos::tejido linfoide::ganglios linfáticos [ANATOMÍA], medicine.disease, Còlon - Càncer - Prognosi, Lymph Node Excision, Histopathology, Lymph Nodes, Neoplasm Grading, Neoplasm Recurrence, Local, business
Abstract

Factor pronòstic; Carcinoma colorectal; Càrrega tumoral Factor pronóstico; Carcinoma colorrectal; Carga tumoral Prognostic factor; Colorectal Carcinoma; Tumor Burden INTRODUCTION: Molecular lymph node (LN) staging in early colorectal cancer (CRC) has demonstrated to be more precise than conventional histopathology pN staging. Tumor budding (TB) and poorly differentiated clusters (PDCs) are associated with LN metastases, recurrences, and lower survival in CRC. We evaluated the correlation between the total tumor load (TTL) in LNs from CRC surgical specimens with patient outcome, TB, and PDC. METHODS: In this retrospective multicentre study, 5,931 LNs from 342 stage I–III CRC were analyzed by both hematoxylin and eosin and molecular detection of tumor cytokeratin 19 mRNA by one-step nucleic acid amplification. TB and PDC were evaluated by hematoxylin and eosin and cytokeratin 19 immunohistochemistry. Results: One-step nucleic acid was positive in 38.3% patients (n = 131). Tumor Budding was low in 45% cases, intermediate in 25%, and high in 30%. Poorly Differentiated Clusters were low-grade G1 in 53%, G2 in 32%, and G3 in 15%. TB and PDC correlated with TTL, high-grade, lymphovascular and perineural invasion, pT, pN and stage (P < 0.001). TB, PDC, and TTL ≥ 6,000 copies/µL were associated with worse overall survival (P = 0.002, P = 0.013, and P = 0.046) and disease-free survival (P < 0.001). Discussion: The implementation of more sensitive molecular methods to assess LN status is a promising alternative approach to pN staging, which could be integrated to other factors to help risk stratification and management of patients with early-stage CRC. This study demonstrates the correlation of the amount of LN tumor burden with TB and PDCs. TTL is related to the outcome and could be used as a new prognostic factor in CRC (see Visual Abstract, Supplementary Digital Content 2, https://links.lww.com/CTG/A512). This work was supported by the Instituto de Salud Carlos III (grants PI17/01304 to J.C and M.C; grant PI16/00766 to F.B., and a Miguel Servet grant to J.C, cofunded by the European Regional Development Fund (ERDF) (CPII18/00026), through the Plan Estatal de Investigación Científica y Técnica y de Innovación, and Agència de Gestió d’Ajuts Universitaris i de Recerca (2017SGR653 and 2017SGR1035). CIBERehd is funded by the Instituto de Salud Carlos III. We also acknowledge the support of the CERCA Programme/Generalitat de Catalunya, and the Xarxa de Bancs de Tumors de Catalunya (XBTC).

Published
2021

4. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer

Author

Ramon Salazar, Chiara Chianese, Evaristo Maiello, Alba Noguerido, Josep Tabernero, Ana Vivancos, Erica Martinelli, Judit Matito, Guillem Argiles, Cristina Santos, Giulia Martini, Ginevra Caratu, Jaume Capdevila, Ariadna Garcia, Francesco M. Mancuso, Julieta Grasselli, Nuria Mulet, Nicola Normanno, Fortunato Ciardello, Enrique Sanz-Garcia, Claudia Cardone, Elena Elez, Frederick S. Jones, Riziero Esposito Abate, Teresa Macarulla, [Elez E, Sanz-García E, Noguerido A, Martini G, Macarulla T, Argilés G, Capdevila J, Garcia A, Tabernero J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Chianese C, Mancuso FM, Caratù G, Matito J, Vivancos A] Grup de Genòmica del Càncer, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Martinelli E] Medical Oncology, Department of Clinical and Experimental Medicine ‘F. Magrassi’, Università della Campania ‘L. Vanvitelli’, Napoli, Italy. [Grasselli J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain. [Mulet N] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Servei d’Oncologia Mèdica, Institut Català d’Oncologia, L'Hospitalet, Spain. Universitat de Barcelona, L'Hospitalet, Spain., Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Elez, E., Chianese, C., Sanz-Garcia, E., Martinelli, E., Noguerido, A., Mancuso, F. M., Caratu, G., Matito, J., Grasselli, J., Cardone, C., Esposito Abate, R., Martini, G., Santos, C., Macarulla, T., Argiles, G., Capdevila, J., Garcia, A., Mulet, N., Maiello, E., Normanno, N., Jones, F., Tabernero, J., Ciardello, F., Salazar, R., and Vivancos, A.

Subjects
0301 basic medicine, Oncology, Male, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Cancer Research, Colorectal cancer, Sang, técnicas de investigación::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::técnicas de investigación::técnicas de laboratorio clínico::técnicas de investigación::biopsia líquida [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], 0302 clinical medicine, Carcinoembryonic antigen, Medicine, Prospective Studies, Prospective cohort study, prognostic biomarker, Diagnosis::Prognosis::Neoplasm Staging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Research Articles, circulating tumor DNA, biology, Metastatic colorectal cancer, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], metastatic colorectal cancer, Hazard ratio, General Medicine, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, MAF, Survival Rate, Blood, 030220 oncology & carcinogenesis, Cohort, Molecular Medicine, Female, diagnóstico::pronóstico::estadificación de neoplasias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Colorectal Neoplasms, Neoplasias::Neoplasias por Localización::Neoplasias del Sistema Digestivo::Neoplasias Gastrointestinales::Neoplasias Intestinales::Neoplasias Colorrectales [ENFERMEDADES], Research Article, medicine.medical_specialty, Citodiagnòstic, Prognostic biomarker, Investigative Techniques::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Investigative Techniques::Clinical Laboratory Techniques::Investigative Techniques::Liquid Biopsy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Oncogene Protein p21(ras), lcsh:RC254-282, Disease-Free Survival, 03 medical and health sciences, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Metàstasi, Càncer colorectal, Internal medicine, Mortalitat, Genetics, Humans, RAS analysis, Mortality, Allele, Survival rate, Alleles, Aged, Retrospective Studies, Circulating tumor DNA, business.industry, Mutació (Biologia), Recte - Càncer - Prognosi, Mutation (Biology), medicine.disease, Confidence interval, 030104 developmental biology, afecciones patológicas, signos y síntomas::procesos patológicos::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Mutation, biology.protein, business, Genètica
Abstract

Metastatic colorectal cancer; RAS analysis; Prognostic biomarker Cáncer colorrectal en metástasis; Análisis RAS; Biomarcador como pronóstico Càncer colorectal en metàstasi; Anàlisi RAS; Biomarcador com a pronòstic Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS‐mutant allele fraction (MAF) in plasma in mCRC. Forty‐seven plasma samples from 37 RAS‐mutated patients with nonresectable metastases were tested for RAS in circulating tumor DNA using BEAMing before first‐ and/or second‐line treatment. RAS MAF was correlated with several clinical parameters (number of metastatic sites, hepatic volume, carcinoembryonic antigen, CA19‐9 levels, primary site location, and treatment line) and clinical outcome [progression‐free survival (PFS) and overall survival (OS)]. An independent cohort of 32 patients from the CAPRI‐GOIM trial was assessed for clinical outcome based on plasma baseline MAF. RAS MAF analysis at baseline revealed a significant correlation with longer OS [Hazard ratios (HR) = 3.514; P = 0.00066]. Patients with lower MAF also showed a tendency to longer PFS, although not statistically significant. Multivariate analysis showed RAS MAFs as an independent prognostic factor in both OS (HR = 2.73; P = 0.006) and first‐line PFS (HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher MAF was progression disease (P = 0.007). Patients with low MAFs at baseline in the CAPRI‐GOIM group also showed better OS [HR = 3.84; 95% confidence intervals (CI) 1.5–9.6; P = 0.004] and better PFS (HR = 2.5; 95% CI: 1.07–5.62; P = 0.033). This minimally invasive test may help in adding an independent factor to better estimate outcomes before initiating treatment. Further prospective studies using MAF as a stratification factor could further validate its utility in clinical practice. This work was supported partially by the Instituto de Salud Carlos III (Ministerio de Economia y Competitividad) and `Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa' grants [FIS PI12-01589 to RS] and RETICC Cancer.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results